UDK: 615.15
L.M. Ganicheva, O.A. Panfilova, A.V. Voronova
ФГБОУ ВО «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской Федерации, кафедра управления и экономики фармации, медицинского и фармацевтического товароведения
Viral hepatitis is an international public health threat. With the adoption of the UN Assembly Resolution in 2016, the problem of hepatitis no longer remains in the shadows. An important step towards eradicating chronic hepatitis C (CHC) is the introduction of direct-acting antiviral drugs into treatment standards. They appeared in the WHO List of Essential Medicines for the first time since 2014. On the territory of the Russian Federation, the number of registered international nonproprietary names increased in 2014–2020 by 3.5 times and at the time of 2020 it was 10. Direct-acting antiviral drugs were included in the Vital and most Essential Drugs List since 2017 (10 %), and by 2020 this indicator had increased by 7 times. In general, in the Russian Federation since 2017, there has been progress in solving a global problem through the use of more effective drugs, which cannot be said about the regions of our country. So, in the Volgograd region, not a single Direct-acting antiviral drugs of preferential leave for the treatment of CHC on an outpatient basis has been registered.
chronic viral hepatitis C, direct-acting antiviral drugs, WHO Essential Medicines List, State Register of Medicines, Vital and most Essential Drugs List, Regional List.
Ганичева Людмила Михайловна – д. фарм. н., профессор, зав. кафедрой управления и экономики фармации, медицинского и фармацевтического товароведения, Волгоградский государственный медицинский университет, e-mail: lmganicheva55@mail.ru